Eli Lilly Expands US Oral GLP-1 Foundayo Prescriptions to 47.5K Against Wegovy
Resolved · supply chain · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-17. Check what remains unresolved below before relying on it.
Which investments are exposed, and through which channels?
Prescription share gains in oral formulations expand Eli Lilly's market capture in metabolic therapeutics, influencing revenue mix versus Novo Nordisk.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly holds approximately 60% of the overall United States weight-loss drug market. |
| What else was confirmed? | Reported factIn the oral GLP-1 pill segment, Novo Nordisk's Wegovy pill leads with 183,000 active prescriptions. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownWeekly IQVIA / Symphony US oral GLP-1 prescription data — Sequential weekly percentage change in Foundayo versus Wegovy pill new-to-brand prescriptions (NBRx). |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly holds approximately 60% of the overall United States weight-loss drug market.
- · In the oral GLP-1 pill segment, Novo Nordisk's Wegovy pill leads with 183,000 active prescriptions.
- · Eli Lilly's Foundayo oral GLP-1 pill has reached 47,500 active prescriptions, narrowing the adoption gap.
Public research record
Research framework · page evidenceCompleted event assessment
commercial market share expansion in oral metabolic treatments
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly holds approximately 60% of the overall United States weight-loss drug market. | 2026-09-17 |
| Interpretation | commercial market share expansion in oral metabolic treatments | LLY |
Countercase, invalidators, and sources
Foundayo prescription growth accelerates past 100,000 quarterly runs, reinforcing Lilly's aggregate market share above 65%.
- · Weekly IQVIA / Symphony US oral GLP-1 prescription data — Sequential weekly percentage change in Foundayo versus Wegovy pill new-to-brand prescriptions (NBRx).
- This Trend is Excellent News for Eli Lilly and Its Investors · 2026-09-17
What remains unresolved
- Base path
- Lilly steadily closes the oral volume differential while Novo Nordisk maintains leadership in absolute oral scripts through established payer placement.
- Adverse path
- Supply constraints in oral formulation manufacturing stall Foundayo distribution, cementing Novo Nordisk's first-mover oral advantage.
- Supportive path
- Foundayo prescription growth accelerates past 100,000 quarterly runs, reinforcing Lilly's aggregate market share above 65%.
- · Weekly IQVIA / Symphony US oral GLP-1 prescription data — Sequential weekly percentage change in Foundayo versus Wegovy pill new-to-brand prescriptions (NBRx).this week
Evidence
- This Trend is Excellent News for Eli Lilly and Its Investors2026-09-17
“Eli Lilly dominates the weight loss drug market with 60% U.S. share and is gaining ground in the new oral GLP-1 pill segment. While Novo Nordisk's Wegovy pill currently leads in prescriptions (183,000 vs. 47,500 for Lilly's Foundayo), the gap is narrowing.”
Supports: Lilly holds 60% US weight loss share and reached 47,500 Foundayo scripts vs Novo's 183,000 Wegovy pill scripts.